Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Assets (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Non-Current Assets for 16 consecutive years, with $374.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 48.74% to $374.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 billion, a 8.65% decrease, with the full-year FY2025 number at $374.0 million, down 48.74% from a year prior.
  • Non-Current Assets was $374.0 million for Q4 2025 at Myriad Genetics, down from $383.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.0 billion in Q1 2021 to a low of -$291.6 million in Q2 2024.
  • A 5-year average of $719.5 million and a median of $830.4 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: plummeted 132.66% in 2024, then surged 234.77% in 2025.
  • Myriad Genetics' Non-Current Assets stood at $835.9 million in 2021, then grew by 10.55% to $924.1 million in 2022, then decreased by 9.87% to $832.9 million in 2023, then dropped by 12.4% to $729.6 million in 2024, then plummeted by 48.74% to $374.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Non-Current Assets are $374.0 million (Q4 2025), $383.3 million (Q3 2025), and $393.0 million (Q2 2025).